Cargando…

Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer

However, ICI therapy has thus far demonstrated limited efficacy in breast cancers, where tumor mutation rates are intermediate. Nonetheless, because of limited but positive signals in early trials, combinations of therapies to enhance anti-tumor immunity, and thus response to ICIs in breast cancer,...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Na, Sugiura, Ayaka, Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shared Science Publishers OG 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558931/
https://www.ncbi.nlm.nih.gov/pubmed/31225469
http://dx.doi.org/10.15698/cst2018.03.129